Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 …
N Folschweiller, J Teixeira, S Joshi, LZ Goldani… - …, 2020 - thelancet.com
Background Women living with HIV (WLWH) are at higher risk of acquisition and
progression of human papillomavirus (HPV) infection. Evidence on effect of HPV vaccination …
progression of human papillomavirus (HPV) infection. Evidence on effect of HPV vaccination …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - Taylor & Francis
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women
JA Kahn, J Xu, BG Kapogiannis, B Rudy… - Clinical infectious …, 2013 - academic.oup.com
Background The objective of this study was to determine whether the 3-dose quadrivalent
human papillomavirus (HPV) vaccine series (HPV-6,-11,-16,-18) is immunogenic and safe in …
human papillomavirus (HPV) vaccine series (HPV-6,-11,-16,-18) is immunogenic and safe in …
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women …
MH Einstein, P Takacs, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
The observer-blind, randomized, age-stratified, head-to-head study (NCT00423046)
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …
EA Joura, A Ulied, C Vandermeulen, MR Figueroa… - Vaccine, 2021 - Elsevier
Background Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
Safety and efficacy of human papillomavirus vaccination for people living with HIV: A systematic review and meta-analysis
Y Zhan, X Liu, Y Feng, S Wu… - International journal of …, 2019 - journals.sagepub.com
The current evidence regarding the safety and immunogenicity of human papillomavirus
(HPV) vaccinations for people living with HIV (PLWH) is unclear. We searched PubMed …
(HPV) vaccinations for people living with HIV (PLWH) is unclear. We searched PubMed …
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled …
S Hu, X Xu, F Zhu, Y Hong, Y Hu, X Zhang… - Human Vaccines & …, 2021 - Taylor & Francis
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and
associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) …
associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) …
[HTML][HTML] HPV serostatus pre-and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: The evri trial
Background HPV antibodies are a marker of past exposure to the virus. Our objective was to
assess HPV serostatus pre-and post-vaccination among HIV-negative women. Methods …
assess HPV serostatus pre-and post-vaccination among HIV-negative women. Methods …
Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25-year-old HIV-seronegative African girls and young …
PS Sow, D Watson-Jones, N Kiviat… - The Journal of …, 2013 - academic.oup.com
Background. Cervical cancer is a major public health problem for women in sub-Saharan
Africa. Availability of a human papillomavirus (HPV) vaccine could have an important public …
Africa. Availability of a human papillomavirus (HPV) vaccine could have an important public …